肿瘤细胞治疗研究
英文原题：The future belongs to those who believe in multiplex CAR T engineering.
毒性和免疫逃逸一直阻碍着 CAR T 细胞在 HER2 阳性实体瘤中取得成功。
在HER2阳性实体瘤中，毒性和免疫逃逸阻碍了CAR T细胞的成功应用。在本期Cell Stem Cell中，Hosking等人提出了一种由iPSC衍生的CAR T细胞产品，该产品经过工程化改造，可实现肿瘤选择性靶向、对免疫抑制性肿瘤微环境的抵抗、增强的持久性和浸润能力，以及减轻抗原逃逸。
Toxicity and immune evasion have hindered the success of CAR T cells in HER2-positive solid tumors. In this issue of Cell Stem Cell, Hosking et al. present an iPSC-derived CAR T cell product engineered for tumor-selective targeting, resistance to the immunosuppressive tumor microenvironment, enhanced persistence and trafficking, and mitigation of antigen escape.
MEMBER ACCOUNT
登录成功会直接打开下一页。
